Fig. 6: NCT-58 suppresses BCSC-like properties and downregulates the expression of HSF-1, HSP70, and HSP90 in vivo.
From: The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells
A, B Following exposure to NCT-58, CD44 and ALDH1 expression levels were markedly downregulated in JIMT-1 xenograft tumors. The fluorescence intensities of CD44 (A, ***p < 0.001, n = 6) and ALDH1 (B, ***p < 0.001, n = 6) were analyzed using a histogram tool. C–E Effect of NCT-58 on induction of the HSR in vivo. C NCT-58 administration resulted in a decrease in nuclear expression of HSF-1 (green). Fluorescence intensity of HSF-1 localized in the nuclei is represented in arbitrary units as defined by the software using the intensity profile tool. D, E NCT-58 downregulated both HSP70 and HSP90 expression. Quantitative graphs of fluorescence intensities of HSP70 (D, **p < 0.01, n = 6) and HSP90 (E, ***p < 0.001, n = 6) signal, shown in the bottom panels, respectively. Tumors were harvested within 24 h of the last administration of NCT-58 for immunohistochemistry assessment. Data were analyzed by unpaired Student’s t-test.
